Repository logo
 
Publication

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

2023Journal article Open access
Simple item page
dc.contributor.authorGampenrieder, SP
dc.contributor.authorDezentjé, V
dc.contributor.authorLambertini, M
dc.contributor.authorde Nonneville, A
dc.contributor.authorMarhold, M
dc.contributor.authorLe Du, F
dc.contributor.authorCortés Salgado, A
dc.contributor.authorAlpuim Costa, D
dc.contributor.authorVaz Batista, M
dc.contributor.authorChic Ruché, N
dc.contributor.authorTinchon, C
dc.contributor.authorPetzer, A
dc.contributor.authorBlondeaux, E
dc.contributor.authorDel Mastro, L
dc.contributor.authorTargato, G
dc.contributor.authorBertucci, F
dc.contributor.authorGonçalves, A
dc.contributor.authorViret, F
dc.contributor.authorBartsch, R
dc.contributor.authorMannsbart, C
dc.contributor.authorDeleuze, A
dc.contributor.authorRobert, L
dc.contributor.authorSaavedra Serrano, C
dc.contributor.authorGion Cortés, M
dc.contributor.authorSampaio-Alves, M
dc.contributor.authorVitorino, M
dc.contributor.authorPecen, L
dc.contributor.authorSinger, C
dc.contributor.authorHarbeck, N
dc.contributor.authorRinnerthaler, G
dc.contributor.authorGreil, R
dc.date.accessioned2022-12-29T16:48:28Z
dc.date.available2022-12-29T16:48:28Z
dc.date.issued2023
dc.description.abstractBackground: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. Patients and methods: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. Results: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). Conclusions: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationESMO Open. 2022 Dec 21;8(1):100747.pt_PT
dc.identifier.doi10.1016/j.esmoop.2022.100747pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/42901
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectNeoplasias de Mama Triplo Negativaspt_PT
dc.subjectReceptor ErbB-2pt_PT
dc.subjectReceptor, ErbB-2pt_PT
dc.subjectTriple Negative Breast Neoplasmspt_PT
dc.titleInfluence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Grouppt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage100747pt_PT
oaire.citation.titleESMO Openpt_PT
oaire.citation.volume8pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Gampenrieder-2023-Influence-of-her-expression-on-prog.pdf
Size:
457.6 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ICO - Artigos